Comparison of the initial baseline values for biomarkers in the vascular wall in the area of atherosclerotic lesions from patients with progression of atherosclerosis (G A1) to the values from patients without this outcome (G A2) revealed the following differences: the level of the Bax marker was increased 1.3 times, while the sFas level was reduced 1.9 times in G A1 patients compared with G A2 patients (p<0.001, Figures 3 and 4). This evidence concerns the gene BAX and atherosclerosis.